Journal
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
Volume 26, Issue 1, Pages 103-111Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.ijdevneu.2007.08.012
Keywords
retinopathy of prematurity; prematurity; attention deficit hyperactivity disorder; neuroprotection; dopamine
Categories
Funding
- NCRR NIH HHS [M01 RR000082-370652, M01 RR000082-38S10673, M01 RR000082-390673, M01 RR000082-36A10652, P51 RR000166-430161, M01 RR000082-36A10648, M01 RR000082-380713, M01 RR000082-380673, M01 RR000037, P51 RR000166, P51 RR000166-430162, M01 RR000082, M01 RR000082-380718, M01 RR000082-38S10713, M01 RR000082-38S10718, M01 RR000082-38S10652, M01 RR000082-380652, P51 RR000166-440161, M01 RR000082-39S10673, M01 RR000082-370673, P51 RR000166-440162, M01 RR000082-400673, M01 RR000082-410673, M01 RR000037-440874, M01 RR000037-450874, P51 RR000166-455493] Funding Source: Medline
- NICHD NIH HHS [R01 HD052820, R21 HD042213, R01 HD038782-03, R01 HD038782-01A2, R01 HD038782-02, R01 HD038782, R21 HD042213-02, R21 HD042213-01, R01 HD052820-01A2, R01 HD038782-04, R21 HD042213-03] Funding Source: Medline
Ask authors/readers for more resources
Fifteen years of evidence have established that the cytokine erythropoietin offers promise as a treatment for brain injury. In particular, neonatal brain injury may be reduced or prevented by early treatment with recombinant erythropoietin. Extreme prematurity and perinatal asphyxia are common conditions associated with poor neurodevelopmental outcomes including cerebral palsy, mental retardation, hearing or visual impairment, and attention deficit hyperactivity disorder. When high doses of erythropoietin are administered systemically, a small proportion crosses the blood-brain barrier and can protect against hypoxic-ischemic brain injury. In addition to other protective effects, erythropoietin can specifically protect dopaminergic neurons. Since reduced dopamine neurotransmission contributes to attention deficit hyperactivity disorder, this condition may be amenable to erythropoietin treatment. This review focuses on the potential application of erythropoietin as a neuroprotectant with regard to neurologic complications of extreme prematurity, including attention deficit hyperactivity disorder. Recent concerns that early erythropoietin might exacerbate the pathologic neovascularization associated with retinopathy of prematurity are addressed. Published by Elsevier Ltd on behalf of ISDN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available